Tyler Research Institute, LLC.

Tyler, Texas 75703

12 studies enrolling now · 46 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Fistulizing Crohns Disease, Inflammatory Bowel Diseases, Moderately to Severely Active Crohn Disease, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Perianal Crohns Disease, Pouchitis, Ulcerative Colitis, Ulcerative Colitis Chronic

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease — Recruiting now
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — Recruiting now
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Recruiting now
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease — Running, not enrolling
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Stopped early
• An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice — Stopped early
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection — Stopped early
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Triple Combination Therapy in High Risk Crohn's Disease (CD) — Completed
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission — Stopped early
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) — Status unconfirmed
• Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed